5
|
Tarjus A, Martínez-Martínez E, Amador C, Latouche C, El Moghrabi S, Berger T, Mak TW, Fay R, Farman N, Rossignol P, Zannad F, López-Andrés N, Jaisser F. Neutrophil Gelatinase-Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. Hypertension 2015; 66:158-66. [PMID: 25987661 DOI: 10.1161/hypertensionaha.115.05431] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 03/18/2015] [Indexed: 01/19/2023]
Abstract
Activation of the mineralocorticoid receptor has been shown to be deleterious in cardiovascular diseases (CVDs). We have recently shown that lipocalin 2 (Lcn2), or neutrophil gelatinase-associated lipocalin (NGAL), is a primary target of aldosterone/mineralocorticoid receptor in the cardiovascular system. Lcn2 is a circulating protein, which binds matrix metalloproteinase 9 and modulates its stability. We hypothesized that Lcn2 could be a mediator of aldosterone/mineralocorticoid receptor profibrotic effects in the cardiovascular system. Correlations between aldosterone and profibrotic markers, such as procollagen type I N-terminal peptide, were investigated in healthy subjects and subjects with abdominal obesity. The implication of Lcn2 in the mineralocorticoid pathway was studied using Lcn2 knockout mice subjected to a nephrectomy/aldosterone/salt (NAS) challenge for 4 weeks. In human subjects, NGAL/matrix metalloproteinase 9 was positively correlated with plasma aldosterone and fibrosis biomarkers. In mice, loss of Lcn2 prevented the NAS-induced increase of plasma procollagen type I N-terminal peptide, as well as the increase of collagen fibers deposition and collagen I expression in the coronary vessels and the aorta. The lack of Lcn2 also blunted the NAS-induced increase in systolic blood pressure. Ex vivo, treatment of human fibroblasts with recombinant Lcn2 induced the expression of collagen I and the profibrotic galectin-3 and cardiotrophin-1 molecules. Our results showed that Lcn2 plays a key role in aldosterone/mineralocorticoid receptor-mediated vascular fibrosis. The clinical data indicate that this may translate in human patients. Lcn2 is, therefore, a new biotarget in cardiovascular fibrosis induced by mineralocorticoid activation.
Collapse
Affiliation(s)
- Antoine Tarjus
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Ernesto Martínez-Martínez
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Cristian Amador
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Céline Latouche
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Soumaya El Moghrabi
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Thorsten Berger
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Tak W Mak
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Renaud Fay
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Nicolette Farman
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Patrick Rossignol
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Faiez Zannad
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Natalia López-Andrés
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.)
| | - Frédéric Jaisser
- From the INSERM UMR 1138 Team 1, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France (A.T., C.A., C.L., S.E.M., N.F., F.J.); NAVARRABIOMED-FUNDACIÓN MIGUEL SERVET, Pamplona, Spain (E.M.-M., N.L.-A.); The Campbell Family Institute for Cancer Research, University Health Network, Toronto, ON, Canada (T.B., T.W.M.); INSERM, Centre d'Investigations Cliniques-Plurithématique 1433, CHU de Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); Université de Lorraine, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.); and INI-CRCT F-CRIN, Nancy, France (R.F., P.R., F.Z., N.L.-A., F.J.).
| |
Collapse
|